Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 172

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 172
---
 in the best interests of the Company and its stockholders. There can be no assurance, however, that the Company’s current strategic direction, or the Kineta Board of Directors’ evaluation of strategic alternatives, will result in any initiatives, agreements, transactions or plans that will further enhance stockholder value. In addition, given the current restructuring of Kineta’s operations and recent reduction in force, it may be difficult to evaluate the Company’s current business and future prospects on the basis of historical operating performance. Kineta may not realize any additional value in a strategic transaction. Potential counterparties in a strategic transaction involving Kineta may place minimal or no value on the Company’s assets. Further, the development and any potential commercialization of Kineta’s product candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving the Company may choose not to spend additional resources for the development of Kineta’s product candidates and may attribute little or no value, in such a transaction, to those product candidates. If Kineta is successful in completing a strategic transaction, it may be exposed to other operational and financial risks. Although there can be no assurance that a strategic transaction will result from the process Kineta has undertaken to identify and evaluate strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of the Company’s management, and the diversion of management’s attention may disrupt the Company’s business. The negotiation and consummation of any such transaction may also require more time or greater cash resources than Kineta anticipates and expose the Company to other operational and financial risks, including:

| • |     | inability to retain key employees of the Company or any merged business; |

| • |     | increased near-term and long-term expenditures; |

| • |     | exposure to unknown liabilities; |

| • |     | higher than expected acquisition or integration costs; |

| • |     | incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; |

| • |     | write-downs of assets or incurrence of non-recurring, impairment or other charges; |

| • |     | increased amortization expenses; |

| • |     | difficulty and cost in combining the operations and personnel of any acquired business with its operations and personnel; |

| • |     | impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership; and |